Pegylated interferon and ribavirin dosing strategies to enhance sustained virologic response

Eric W Chak, Sammy Saab

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Hepatitis C virus (HCV) affects about 170 million people worldwide and is the most common chronic blood borne infection in the United States. Since the advent of blood screening protocols in the early 1990s, injection drug use has become the leading cause of infection. Hepatitis C can have both hepatic and nonhepatic manifestations of infection. Hepatic manifestations include hepatic fibrosis, cirrhosis, liver cancer, and liver failure. The standard treatment for chronic HCV is combination therapy with pegylated interferon-α and ribavirin. Although pegylated interferon and ribavirin has been used against HCV for close to a decade, advances in therapy have centered on doses and treatment durations. There has been increasing interest in applying on-treatment response or viral kinetics to predict antiviral response rates and shape therapeutic intervention. Protease inhibitors are a promising adjuvant to combination therapy, but their efficacy and safety are still under investigation.

Original languageEnglish (US)
Pages (from-to)147-154
Number of pages8
JournalCurrent Hepatitis Reports
Issue number3
StatePublished - Aug 2010
Externally publishedYes


  • Chronic hepatitis C
  • Hepatitis C virus
  • Pegylated interferon-α
  • Protease inhibitors
  • Ribavirin
  • Viral kinetics

ASJC Scopus subject areas

  • Hepatology
  • Virology


Dive into the research topics of 'Pegylated interferon and ribavirin dosing strategies to enhance sustained virologic response'. Together they form a unique fingerprint.

Cite this